Study of BDTX-1535 in Recurrent High-Grade Glioma (HGG) Participants With EGFR Alterations or Fusions
Status:
Recruiting
Trial end date:
2025-10-31
Target enrollment:
Participant gender:
Summary
This study will administer the investigational drug, BDTX-1535 to eligible patients with
recurrent high-grade glioma. BDTX-1535 was designed to block a growth signal important to
some cancers. BDTX-1535 is being tested in this study to see if it can be given safely to
people who have tumors that can be dependent on that growth signal because of changes in a
protein called EGFR. These gene changes are called amplifications, mutations, fusions or
alterations and are found only in the tumors.
Phase:
Early Phase 1
Details
Lead Sponsor:
St. Joseph's Hospital and Medical Center, Phoenix
Collaborators:
Barrow Neurological Institute Ivy Brain Tumor Center